Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
13.80
-0.80 (-5.48%)
At close: Dec 10, 2025, 4:00 PM EST
14.00
+0.20 (1.45%)
After-hours: Dec 10, 2025, 7:10 PM EST
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 45 employees as of December 31, 2024. The number of employees decreased by 31 or -40.79% compared to the previous year.
Employees
45
Change (1Y)
-31
Growth (1Y)
-40.79%
Revenue / Employee
n/a
Profits / Employee
-$1,580,311
Market Cap
746.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | 73 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FULC News
- 11 hours ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 days ago - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - GlobeNewsWire
- 2 days ago - Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - Benzinga
- 3 days ago - Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript - Seeking Alpha
- 4 days ago - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire
- 5 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 - GlobeNewsWire
- 5 weeks ago - Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire